Canada - English - Health Canada

teva canada limited - raloxifene hydrochloride - tablet - 60mg - raloxifene hydrochloride 60mg - estrogen agonist-antagonists

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet - excipient ingredients: crospovidone; magnesium stearate; hyprolose; titanium dioxide; lactose; colloidal anhydrous silica; macrogol 8000; hypromellose - the prevention and treatment of osteoporosis in post-menopausal women.,the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.,the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.,high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer greater than 1.66 percent (based on the modified gail model). among the factors included in the modified gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - bazedoxifene acetate - pale yellow tablet, major axis: 11.2 mm, minor axis: 6.2 mm, thickness: 5.0 mm

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - raloxifene hydrochloride - tablet - 60mg

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-

United States - English - NLM (National Library of Medicine)

eli lilly and company - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-y

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - raloxifene hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; glycine; colloidal anhydrous silica; povidone; polysorbate 80; crospovidone; magnesium stearate; titanium dioxide; hypromellose; carnauba wax; macrogol 400 - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; povidone; microcrystalline cellulose; polysorbate 80; colloidal anhydrous silica; glycine; titanium dioxide; hypromellose; carnauba wax; macrogol 400 - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - raloxifene hydrochloride -